Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
Company Details
- Employees
- 21
- Founded
- -
- Address
- 5820 Oberlin Drive, Suite 101, San Diego,california 92121,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- belitebio.com
- Keywords
- RBP4, Drug Development, Dry Age-Related Macular Degeneration, Stargardt Disease, Diabetes, NASH, NAFLD.
- HQ
- San Diego, California
Belite Bio Questions
Belite Bio's website is belitebio.com
Belite Bio's LinkedIn profile is https://www.linkedin.com/company/belitebio
Belite Bio has
21 employees.
View email and phone details for 21
employees at Belite Bio.
Belite Bio's industry is
Biotechnology Research
Belite Bio's top competitors are
Centessa Pharmaceuticals,
Grace Therapeutics, Inc.,
Alkeus Pharmaceuticals, Inc.,
Salubris Biotherapeutics,
Endeavor Biomedicines,
Intelligene 智新生技,
Xaira Therapeutics,
Cidara Therapeutics,
Cerevance,
Lin Bioscience.
Belite Bio's categories are Biotechnology Research
Belite Bio's founding year is 2018
